SMOFKABIVEN amino acids 5.1% / lipids 3.8% / glucose 12.7% / electrolytes 0.7% emulsion for intravenous infusion bag 986 mL Australia - English - Department of Health (Therapeutic Goods Administration)

smofkabiven amino acids 5.1% / lipids 3.8% / glucose 12.7% / electrolytes 0.7% emulsion for intravenous infusion bag 986 ml

fresenius kabi australia pty ltd - medium chain triglycerides, quantity: 60 g/l; soya oil, quantity: 60 g/l; olive oil, quantity: 50 g/l; fish oil - rich in omega-3 acids, quantity: 30 g/l - injection, intravenous infusion - excipient ingredients: sodium oleate; egg lecithin; sodium hydroxide; glycerol; dl-alpha-tocopherol; water for injections - parenteral nutrition for adult patients and paediatric patients aged 2 years and above when oral or enteral nutrition is impossible, insufficient or contraindicated.

Remifentanil-AFT, remifentanil (as hydrochloride) 2 mg, powder for injection, glass vial Australia - English - Department of Health (Therapeutic Goods Administration)

remifentanil-aft, remifentanil (as hydrochloride) 2 mg, powder for injection, glass vial

aft pharmaceuticals pty ltd - remifentanil hydrochloride, quantity: 2.194 mg (equivalent: remifentanil, qty mg) - injection, powder for - excipient ingredients: hydrochloric acid; glycine - remifentanil is indicated:,? as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical procedures including cardiac surgery in adults,? as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical procedures but not cardiac procedures in children aged 1 to 12 years,? for continuation as an analgesic into the immediate post-operative period under the close supervision of medically qualified persons trained in the use of anaesthetic drugs, during transition to longer acting analgesia following adult cardiac surgery,when endotracheal intubation and controlled ventilation are anticipated.,? for provision of analgesia and sedation in mechanically ventilated intensive care patients.

Remifentanil-AFT, remifentanil (as hydrochloride) 5 mg, powder for injection, glass vial Australia - English - Department of Health (Therapeutic Goods Administration)

remifentanil-aft, remifentanil (as hydrochloride) 5 mg, powder for injection, glass vial

aft pharmaceuticals pty ltd - remifentanil hydrochloride, quantity: 5.485 mg (equivalent: remifentanil, qty mg) - injection, powder for - excipient ingredients: hydrochloric acid; glycine - remifentanil is indicated:,? as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical procedures including cardiac surgery in adults,? as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical procedures but not cardiac procedures in children aged 1 to 12 years,? for continuation as an analgesic into the immediate post-operative period under the close supervision of medically qualified persons trained in the use of anaesthetic drugs, during transition to longer acting analgesia following adult cardiac surgery,when endotracheal intubation and controlled ventilation are anticipated.,? for provision of analgesia and sedation in mechanically ventilated intensive care patients.

Remifentanil-AFT, remifentanil (as hydrochloride) 1 mg, powder for injection, glass vial Australia - English - Department of Health (Therapeutic Goods Administration)

remifentanil-aft, remifentanil (as hydrochloride) 1 mg, powder for injection, glass vial

aft pharmaceuticals pty ltd - remifentanil hydrochloride, quantity: 1.097 mg (equivalent: remifentanil, qty mg) - injection, powder for - excipient ingredients: hydrochloric acid; glycine - remifentanil is indicated:,? as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical procedures including cardiac surgery in adults,? as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical procedures but not cardiac procedures in children aged 1 to 12 years,? for continuation as an analgesic into the immediate post-operative period under the close supervision of medically qualified persons trained in the use of anaesthetic drugs, during transition to longer acting analgesia following adult cardiac surgery,when endotracheal intubation and controlled ventilation are anticipated.,? for provision of analgesia and sedation in mechanically ventilated intensive care patients.

Glycine 1.5% Irrigation (Biomed) New Zealand - English - Medsafe (Medicines Safety Authority)

glycine 1.5% irrigation (biomed)

biomed limited - glycine 1.5% - irrigation - 1.5 % - active: glycine 1.5% excipient: water for injection

Glycine Irrigation (Pharmacia) New Zealand - English - Medsafe (Medicines Safety Authority)

glycine irrigation (pharmacia)

pfizer new zealand limited - glycine 1.5% - irrigation - 1.5 % - active: glycine 1.5%

LIDOCAINE-BAXTER lidocaine (lignocaine) hydrochloride (as monohydrate) 50 mg/5 mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

lidocaine-baxter lidocaine (lignocaine) hydrochloride (as monohydrate) 50 mg/5 ml solution for injection ampoule

baxter healthcare pty ltd - lidocaine hydrochloride monohydrate, quantity: 53.3 mg (equivalent: lidocaine hydrochloride, qty 50 mg) - injection, solution - excipient ingredients: hydrochloric acid; water for injections; sodium chloride; sodium hydroxide - for production of local or regional anaesthesia by nerve block, infiltration injection, caudal or other epidural blocks. treatment or prophylaxis of life-threatening ventricular arrhythmias, including those associated with myocardial infarction, general anaesthesia in patients predisposed to ventricular arrhythmias, digitalis intoxication, or following resuscitation from cardiac arrest.

LIDOCAINE-BAXTER lidocaine (lignocaine) hydrochloride (as monohydrate) 200 mg/20 mL solution for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

lidocaine-baxter lidocaine (lignocaine) hydrochloride (as monohydrate) 200 mg/20 ml solution for injection vial

baxter healthcare pty ltd - lidocaine hydrochloride monohydrate, quantity: 213.2 mg (equivalent: lidocaine hydrochloride, qty 200 mg) - injection, solution - excipient ingredients: water for injections; sodium chloride; hydrochloric acid; sodium hydroxide - for production of local or regional anaesthesia by nerve block, infiltration injection, caudal or other epidural blocks. treatment or prophylaxis of life-threatening ventricular arrhythmias, including those associated with myocardial infarction, general anaesthesia in patients predisposed to ventricular arrhythmias, digitalis intoxication, or following resuscitation from cardiac arrest.

LIDOCAINE-BAXTER lidocaine (lignocaine) hydrochloride (as monohydrate) 40 mg/2 mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

lidocaine-baxter lidocaine (lignocaine) hydrochloride (as monohydrate) 40 mg/2 ml solution for injection ampoule

baxter healthcare pty ltd - lidocaine hydrochloride monohydrate, quantity: 42.66 mg (equivalent: lidocaine hydrochloride, qty 40 mg) - injection, solution - excipient ingredients: sodium hydroxide; water for injections; sodium chloride; hydrochloric acid - for production of local or regional anaesthesia by nerve block, infiltration injection, caudal or other epidural blocks. treatment or prophylaxis of life-threatening ventricular arrhythmias, including those associated with myocardial infarction, general anaesthesia in patients predisposed to ventricular arrhythmias, digitalis intoxication, or following resuscitation from cardiac arrest.

LIDOCAINE-BAXTER lidocaine (lignocaine) hydrochloride (as monohydrate) 20 mg/2 mL solution for injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

lidocaine-baxter lidocaine (lignocaine) hydrochloride (as monohydrate) 20 mg/2 ml solution for injection ampoule

baxter healthcare pty ltd - lidocaine hydrochloride monohydrate, quantity: 21.32 mg (equivalent: lidocaine hydrochloride, qty 20 mg) - injection, solution - excipient ingredients: sodium hydroxide; sodium chloride; hydrochloric acid; water for injections - for production of local or regional anaesthesia by nerve block, infiltration injection, caudal or other epidural blocks. treatment or prophylaxis of life-threatening ventricular arrhythmias, including those associated with myocardial infarction, general anaesthesia in patients predisposed to ventricular arrhythmias, digitalis intoxication, or following resuscitation from cardiac arrest.